A retrospective analysis of the efficacy and safety of imatinib for advanced gastrointestinal stromal tumor in elderly patients
Key Points
Elderly patients treated with imatinib showed notable efficacy for advanced gastrointestinal stromal tumors, with a favorable safety profile.
The study revealed that the median progression-free survival was significantly improved in this demographic group, indicating positive outcomes.
Retrospective analysis highlighted the importance of age considerations when utilizing imatinib for treatment in advanced cases.
Findings suggest that imatinib may be a viable treatment option for elderly patients with gastrointestinal stromal tumors, warranting further investigation.